Keyphrases
Acinetobacter Baumannii (A. baumannii)
20%
Antibiotics
60%
Azithromycin
100%
Bacterial Pathogens
20%
Bacterial Strains
20%
Cell Envelope
20%
Clindamycin
20%
Clinical Significance
20%
Clinically Significant
20%
E. Coli ST131
20%
Erythromycin
40%
Escherichia Coli
20%
Escherichia Coli ATCC 25922
20%
Eukaryotic Cells
20%
Gram-negative Bacteria
20%
Gram-negative Pathogens
100%
Gram-positive Bacteria
20%
IC50
20%
In Vivo Pharmacokinetics
20%
Klebsiella Pneumoniae (K. pneumoniae)
20%
Linezolid
20%
Low Cytotoxicity
20%
Main Activities
20%
Multidrug-resistant Gram-negative Bacteria
20%
Peptide Concentration
20%
Pharmacodynamic Study
20%
Pharmacokinetics-pharmacodynamics (PK-PD)
20%
Potentiator
100%
Repurposing
100%
Rifampicin
100%
Toxicity Study
20%
Vancomycin
20%
Pharmacology, Toxicology and Pharmaceutical Science
Acinetobacter Baumannii
20%
Antibiotics
60%
Antiinfective Agent
20%
Azithromycin
100%
Clindamycin
20%
Cytotoxicity
20%
Erythromycin
40%
Escherichia coli
60%
Gram Positive Bacterium
20%
IC50
20%
Infectious Agent
100%
Klebsiella pneumoniae
20%
Linezolid
20%
Pharmacodynamics
20%
Pharmacokinetic
20%
Repurposing
100%
Rifampicin
100%
Vancomycin
20%
Immunology and Microbiology
Acinetobacter Baumannii
12%
Bacterial Strain
12%
Cytotoxicity
12%
Escherichia coli
37%
Eukaryotic Cell
12%
Gram-Positive Bacteria
12%
IC50
12%
Infectious Agent
100%
Klebsiella pneumoniae
12%
Peptides
100%
Pharmacodynamics
12%
Pharmacokinetic
12%